Day One Biopharmaceuticals Inc (NASDAQ:DAWN) shares, rose in value, with the stock price up by 6.60% to the previous day’s close as strong demand from buyers drove the stock to $15.43.
Actively observing the price movement in the recent trading, the stock is buoying the session at $14.47, falling within a range of $14.26 and $16.23. Referring to stock’s 52-week performance, its high was $18.07, and the low was $10.90. On the whole, DAWN has fluctuated by 13.25% over the past month.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
With the market capitalization of Day One Biopharmaceuticals Inc currently standing at about $1.35 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2024-Oct-30.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 59.57M, with a low estimate of 16M and a high estimate of 25.9M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 20.1M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that DAWN’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of DAWN currently trading nearly 6.91% and 8.68% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 63.66, while the 7-day volatility ratio is showing 3.60% which for the 30-day chart, stands at 4.30%. Furthermore, Day One Biopharmaceuticals Inc (DAWN)’s beta value is -1.52, and its average true range (ATR) is 0.70.
A comparison of Day One Biopharmaceuticals Inc (DAWN) with its peers suggests the former has fared considerably weaker in the market. DAWN showed an intraday change of 6.60% in today’s session so far, and over the past year, it grew by 30.39%%.
Data on historical trading for Day One Biopharmaceuticals Inc (NASDAQ:DAWN) indicates that the trading volumes over the past 10 days have averaged 0.85 and over the past 3 months, they’ve averaged 958.08K. According to company’s latest data on outstanding shares, there are 87.23 million shares outstanding.
Nearly 32.41% of Day One Biopharmaceuticals Inc’s shares belong to company insiders and institutional investors own 73.68% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 15.98 million shares as on 2024-10-15, resulting in a short ratio of 15.49. According to the data, the short interest in Day One Biopharmaceuticals Inc (DAWN) stood at 1974.00 of shares outstanding as of 2024-10-15; the number of short shares registered in 2024-09-13 reached 15.1 million. The stock has risen by 5.65% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the DAWN stock heading into the next quarter.
